Tulsa Clinical Research, based in Tulsa Oklahoma, was founded by Ralph W. Richter, MD, FACP in 1986. Dr. Richter also serves as Director of the Alzheimer’s Disease Research Unit at St. John Medical Center and maintains a practice in neurology and neuropsychiatry. They are presently participating in a number of clinical trials. The Tahlequah Daily Press reports Tulsa Clinical Research screened its first participant in a new, national Alzheimer’s disease trial called T2 Project AD—evaluating the investigational drug troriluzole (BHV-4157), potentially protecting against, slowing and eventually improving memory and thinking problems that increase as Alzheimer’s progresses.
Tulsa Clinical Research currently seeks eligible participants. Participants must be between ages 50 to 85, diagnosed with mild-to-moderate Alzheimer’s disease and currently treated with medications for at least three months. Each participant must have a study partner who has regular contact with the clinical trial candidate and can attend study visits.
What is Troriluzole?
First approved by the FDA in 1995 to slightly slow disease progression in patients with Amyotrophic Lateral Sclerosis (ALS), it is a investigational product owned by Biohaven Pharma. According to Biohaven Pharma, “Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. The primary mode of action of troriluzole is reducing synaptic levels of glutamate. Troriluzole increases glutamate uptake from the synapse, by augmenting the expression and function of excitatory amino acid transporters (i.e., EAAT2) located on glial cells that play a key role in clearing glutamate from the synapse. Glutamatergic dysfunction is implicated in the pathophysiology of a broad range of disorders including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Alzheimer’s disease (AD), anxiety, depression, obsessive compulsive disorder (OCD), chronic pain, and a variety of cancers. The therapeutic potential of troriluzole is supported by clinical and translational research studies conducted with riluzole in a variety of these indications.”Source: www.tahlequahdailypress.com